The evaluation of the cost-effectiveness and cost-utility of Palbociclib and Ribociclib in the treatment of women with stage IV breast cancer, using real-world data, is crucial in understanding the value these treatments provide within a clinical and economic context. Stage IV breast cancer, also known as metastatic breast cancer, presents one of the most significant challenges in oncology due to its advanced progression and the complexity of treatment options. In recent years, targeted therapies such as Palbociclib and Ribociclib, both of which are cycling-dependent kinase inhibitors, have been introduced as promising options for treating HR-positive, HER2-negative metastatic breast cancer. These therapies, however, come with high costs, raising questions about their value in terms of both clinical outcomes and economic implications
HTML PDFShare this article
Pharmacoeconomics: Open Access received 106 citations as per Google Scholar report
